The headline sounds almost too good to be true — an 85% remission rate for chronic spontaneous urticaria, a condition that leaves millions of people covered in unpredictable, maddening hives for months or even years at a stretch. But the real story is more nuanced than a single breakthrough pill. That 85% figure actually comes from accumulated real-world data on omalizumab (brand name Xolair), a biologic injection that has been available since 2014, not from one dramatic new approval. In real-world studies, roughly 85% of patients report treatment effectiveness with omalizumab, and a Greek population study found complete response in 86.3% of patients. Those are genuinely impressive numbers — but they reflect a drug that has been on the market for over a decade, not the latest laboratory miracle.
What is new, and genuinely exciting, is the wave of treatments that arrived in 2025 and the pipeline candidate that may change the game entirely. The FDA approved dupilumab (Dupixent) in April 2025 and remibrutinib (Rhapsido) in September 2025, giving patients and clinicians meaningfully different options for the first time in years. Meanwhile, barzolvolimab — an investigational anti-KIT antibody from Celldex Therapeutics — posted phase 2 results showing up to 71% complete response at 52 weeks, with 41% of patients still in complete response seven months after stopping the drug altogether. That durability is unprecedented in this field. This article breaks down what the 85% claim actually means, how each new and emerging treatment works, what the clinical data really shows, and what patients dealing with CSU — and their caregivers, many of whom are navigating overlapping health challenges — should understand about the road ahead.
Table of Contents
- Where Does the 85% Remission Rate for Chronic Spontaneous Urticaria Actually Come From?
- Dupilumab — The First New Targeted Therapy for CSU in Over a Decade
- Remibrutinib — The First Oral Targeted Therapy for CSU
- Barzolvolimab — The Pipeline Drug That Could Rewrite the Standard of Care
- Why CSU Is Particularly Burdensome for Older Adults and Dementia Caregivers
- How to Talk to a Doctor About Newer CSU Treatments
- What the Next Two Years Could Look Like for CSU Treatment
- Conclusion
- Frequently Asked Questions
Where Does the 85% Remission Rate for Chronic Spontaneous Urticaria Actually Come From?
The 85% figure that circulates in headlines traces back to real-world outcome studies of omalizumab, not a single clinical trial for a brand-new drug. In clinical practice — as opposed to the controlled environment of a randomized trial — approximately 85% of CSU patients on omalizumab report that the treatment is effective. A Chinese study found 91.1% complete response at week 12, and a separate survey showed roughly 85% of patients felt the best possible control of their hives had been achieved. These are strong results, and they help explain why omalizumab has remained the backbone of CSU treatment for years. Complete remission, defined as total absence of hives, occurs in more than half of treated patients, with one study putting that number at 57%.
But there is a meaningful gap between “treatment effectiveness” and “remission,” and headlines tend to blur that distinction. Effectiveness can mean fewer hives, less itching, or improved quality of life — all valuable, but not the same as being hive-free. For caregivers and patients researching treatments, the takeaway is that omalizumab works well for most people, but roughly 15–20% of patients do not respond adequately, and even among responders, complete and lasting remission is not guaranteed. That unmet need is exactly what drove the development of the newer drugs now reaching the market. One encouraging detail: among omalizumab responders who transitioned to a lower maintenance dose, 79.5% maintained complete hive control, and most eventually achieved sustained, drug-free remission. So for the right patient, omalizumab can be genuinely transformative — it just is not the universal cure that an “85% remission” headline might suggest.
Dupilumab — The First New Targeted Therapy for CSU in Over a Decade
On April 18, 2025, the FDA approved dupilumab (marketed as Dupixent) for adults and adolescents aged 12 and older with CSU that does not respond to antihistamines. This was the first new targeted biologic approved for CSU in more than ten years, and it works through a different mechanism than omalizumab — targeting the interleukin-4 and interleukin-13 pathways rather than IgE. For patients who tried Xolair without adequate relief, dupilumab represents a genuinely different biological approach, not just a me-too drug. The LIBERTY-CSU CUPID trials showed that 43.1% of patients on dupilumab achieved well-controlled disease (defined as a weekly urticaria activity score of 6 or below) compared to 23.4% on placebo. Complete response — meaning a score of zero, no hives at all — was reached by 30.6% at 24 weeks versus 15.9% on placebo.
Those numbers are statistically significant but also worth putting in context: more than half of patients on dupilumab did not achieve complete response. This is not a failure of the drug so much as a reflection of how stubbornly difficult CSU can be to treat. If you or someone you care for has antihistamine-refractory CSU, dupilumab roughly doubles the odds of getting the disease fully under control compared to doing nothing new — a real benefit, but not a guarantee. However, dupilumab is already well-established for conditions like atopic dermatitis and asthma, so many clinicians are familiar with its safety profile and administration. That familiarity can speed up the conversation between patient and doctor. The limitation to flag: dupilumab is a subcutaneous injection, and for patients who are needle-averse or have caregivers managing complex medication schedules — common in households also dealing with dementia care — the logistics of regular injections matter and should be part of the treatment discussion.
Remibrutinib — The First Oral Targeted Therapy for CSU
For patients who want an alternative to injections, September 30, 2025, brought a significant development: the FDA approved remibrutinib, marketed as Rhapsido, as the first targeted oral therapy for CSU in adults whose symptoms are not controlled by H1 antihistamines. Remibrutinib is a first-in-class oral BTK (Bruton tyrosine kinase) inhibitor — a pill, not a shot — and it works by blocking a signaling pathway involved in mast cell activation, one of the central drivers of hive formation. In clinical trials, roughly one-third of patients achieved complete symptom resolution by week 12. That may sound modest compared to the 85% effectiveness figure associated with omalizumab, but the comparison is not apples to apples: remibrutinib was tested specifically in patients whose CSU had already resisted first-line antihistamine therapy, a harder-to-treat population. The practical advantages are notable.
No routine lab monitoring is required, and adverse events were mostly mild. For a patient already juggling a complex medication regimen — or for an older adult whose caregiver is managing multiple prescriptions — the simplicity of a daily pill with a clean safety profile is a real consideration. The oral format also matters for accessibility. Biologic injections like omalizumab and dupilumab often require refrigeration, specialty pharmacy dispensing, and sometimes in-office administration. Remibrutinib can be picked up at a regular pharmacy and taken at home. For people living with cognitive decline or their caregivers, reducing the friction in a treatment regimen is not a minor point — it can be the difference between adherence and missed doses.
Barzolvolimab — The Pipeline Drug That Could Rewrite the Standard of Care
Among all the drugs in development for CSU, barzolvolimab stands out for a reason that no approved therapy can yet match: durability of response after the drug is stopped. Developed by Celldex Therapeutics, barzolvolimab is an anti-KIT monoclonal antibody that works by depleting mast cells — the immune cells directly responsible for releasing histamine and causing hives — rather than simply blocking one signaling molecule. The phase 2 results are striking. In a study of 208 patients, 51.1% on the 150 mg dose achieved complete response (a urticaria activity score of zero) at week 12, compared to just 6.4% on placebo. That response deepened over time, reaching up to 71% complete response at 52 weeks. But the most remarkable data came at the 76-week mark, presented at the EAACI Congress in June 2025: 41% of patients were still in complete response seven months after stopping treatment, and 48% reported that the disease no longer affected their quality of life — while off the drug. No other CSU therapy has shown anything close to this kind of lasting benefit after discontinuation.
The tradeoff is uncertainty. Barzolvolimab is not yet FDA-approved. Two large phase 3 trials — collectively called EMBARQ-CSU, enrolling 1,939 patients — are the largest phase 3 program ever conducted in antihistamine-refractory CSU. Topline data is expected in the fourth quarter of 2026. Retreatment data presented at the AAAAI meeting in March 2026 showed that patients who relapsed and were retreated achieved similar efficacy to their first exposure, which is encouraging. But until phase 3 results are in and the FDA reviews them, barzolvolimab remains a promising candidate, not an available option. Patients and caregivers should be aware of it — and may want to discuss clinical trial eligibility with their dermatologist or allergist — but should not delay pursuing currently approved treatments while waiting.
Why CSU Is Particularly Burdensome for Older Adults and Dementia Caregivers
Chronic spontaneous urticaria is not just an annoyance. The relentless itching, unpredictable flares, and sleep disruption it causes can significantly worsen cognitive function and quality of life — concerns that are amplified in older adults and in households already managing dementia. Sleep deprivation from nighttime hive flares is a known contributor to cognitive decline and caregiver burnout. When someone with early-stage dementia also has poorly controlled CSU, the behavioral agitation and confusion caused by itching can be mistaken for worsening dementia rather than recognized as a treatable skin condition. Older antihistamines like diphenhydramine (Benadryl), which are still commonly used as first-line CSU treatment, carry anticholinergic effects that have been linked to increased dementia risk and acute confusion in elderly patients.
Newer second-generation antihistamines like cetirizine and loratadine are safer in this regard, but this is a critical point that often gets lost: if a loved one with cognitive concerns is taking an older antihistamine for hives, that medication itself may be contributing to cognitive symptoms. This should be discussed explicitly with their physician. The newer targeted therapies — particularly an oral option like remibrutinib that does not require routine lab monitoring — may offer a path to better hive control without the cognitive side effects of older medications. But any medication change in a patient with dementia or cognitive vulnerability should be coordinated carefully between dermatology and neurology or geriatric medicine. The goal is not just clear skin but preserved function and dignity.
How to Talk to a Doctor About Newer CSU Treatments
Many patients and caregivers do not realize that treatment options beyond antihistamines exist, or they assume that if one biologic did not work, nothing else will. The approval of dupilumab and remibrutinib in 2025 changed the landscape meaningfully, and it is worth bringing these names directly into a clinical conversation. A practical approach: bring a printed list of current FDA-approved CSU treatments — omalizumab, dupilumab, and remibrutinib — along with a brief history of what has already been tried and for how long.
Dermatologists and allergists are the specialists most likely to be current on these approvals, but a primary care physician or geriatrician can make the referral. For patients who have not responded to any approved therapy, clinical trials for barzolvolimab or other investigational agents may be an option. ClinicalTrials.gov is the most reliable way to search for active enrollment sites. Caregivers managing a loved one’s health — particularly when dementia complicates communication — can also request that the clinical team document CSU severity and treatment history clearly, making it easier to advocate for step-up therapy or specialist referral.
What the Next Two Years Could Look Like for CSU Treatment
The CSU treatment landscape in early 2026 is more active than it has been at any point in the past decade. Two new FDA-approved drugs arrived in 2025, and the largest-ever phase 3 program in antihistamine-refractory CSU is set to report topline results by late 2026. If barzolvolimab’s phase 3 data confirms what the phase 2 studies showed — durable, off-treatment remission in a substantial fraction of patients — it would represent a genuine paradigm shift, moving the goal from disease control to something closer to a functional cure for some patients.
Even without barzolvolimab, the current options are markedly better than they were two years ago. Patients now have a choice between injectable biologics with different mechanisms (omalizumab targeting IgE, dupilumab targeting IL-4/IL-13) and an oral targeted therapy (remibrutinib inhibiting BTK). That breadth of mechanism matters because CSU is not one disease — it is a syndrome with multiple immunological drivers, and matching the right drug to the right patient is where the field is heading. For caregivers and patients dealing with CSU alongside other chronic conditions, this is a moment worth paying attention to.
Conclusion
The 85% remission rate headline refers to real-world omalizumab data accumulated over more than a decade — impressive, but not a new breakthrough. What is genuinely new is the arrival of dupilumab and remibrutinib in 2025, giving patients and clinicians the first real alternatives to omalizumab for antihistamine-refractory CSU. And on the horizon, barzolvolimab’s unprecedented durability data — 41% of patients maintaining complete response months after stopping treatment — suggests that lasting, drug-free remission may become achievable for a meaningful number of patients once phase 3 results are confirmed.
For anyone living with CSU or caring for someone who is, the practical next step is a conversation with a dermatologist or allergist about whether current treatment is truly optimized. The options have expanded, the mechanisms are different enough to warrant trying a new approach if the current one is falling short, and clinical trials offer access to therapies that may be even more effective. CSU does not have to be something you simply endure — the science has caught up, and more help is on the way.
Frequently Asked Questions
Is there really a new drug with an 85% remission rate for chronic spontaneous urticaria?
Not exactly. The 85% figure comes from real-world studies of omalizumab (Xolair), which has been available since 2014. About 85% of patients report the treatment is effective, and complete remission occurs in more than half. Newer drugs approved in 2025 — dupilumab and remibrutinib — have different efficacy profiles, and the investigational drug barzolvolimab shows up to 71% complete response at 52 weeks, but none carry a verified 85% remission claim.
What is the most promising new drug for CSU?
Barzolvolimab, an anti-KIT monoclonal antibody in phase 3 trials, has shown the most striking results so far. In phase 2, 41% of patients remained in complete response seven months after stopping treatment — a level of durability no approved CSU drug has demonstrated. Phase 3 data from the EMBARQ-CSU program (1,939 patients) is expected in late 2026.
Are there oral treatment options for CSU now?
Yes. Remibrutinib (Rhapsido), approved by the FDA on September 30, 2025, is the first targeted oral therapy for CSU. It is a BTK inhibitor taken as a pill, with no routine lab monitoring required and mostly mild side effects. This is a significant option for patients who prefer not to use injectable biologics.
Can CSU medications affect cognitive function in older adults?
Older first-generation antihistamines like diphenhydramine carry anticholinergic effects that have been associated with increased confusion and dementia risk in elderly patients. Newer second-generation antihistamines and targeted therapies like remibrutinib, dupilumab, and omalizumab do not carry the same anticholinergic burden, making them preferable for older adults or those with cognitive concerns.
How do I know if I should switch from omalizumab to a newer CSU treatment?
If you are on omalizumab and still experiencing frequent hives, significant itching, or sleep disruption, you may be a candidate for dupilumab or remibrutinib, which target different immune pathways. Discuss your symptom history and treatment response with a dermatologist or allergist to determine whether switching or adding a therapy makes sense.
Is barzolvolimab available yet?
No. Barzolvolimab is currently in phase 3 clinical trials and is not FDA-approved. Patients interested in accessing it may be eligible for enrollment in the EMBARQ-CSU trials. Check ClinicalTrials.gov for active study sites.
